[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Izadi-Mood N, Samadi N, Sarmadi S, Eftekhar Z: Papillary serous carcinoma arising from adenomyosis presenting as intramural leiomyoma. Arch Iran Med; 2007 Apr;10(2):258-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary serous carcinoma arising from adenomyosis presenting as intramural leiomyoma.
  • Herein, we reported a patient with papillary serous carcinoma arising from adenomyosis.
  • The patient was a 61-year-old woman who received tamoxifen for treatment of her breast cancer over the past five years.
  • In one of these foci, papillary serous carcinoma was found.
  • [MeSH-major] Carcinoma, Papillary / pathology. Endometriosis / pathology. Leiomyoma / diagnosis. Myometrium / pathology. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Atrophy. Breast Neoplasms / drug therapy. Female. Humans. Middle Aged. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367236.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


2. Krishnamurthy S, Sneige N, Thompson PA, Marcy SM, Singletary SE, Cristofanilli M, Hunt KK, Kuerer HM: Nipple aspirate fluid cytology in breast carcinoma. Cancer; 2003 Apr 25;99(2):97-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nipple aspirate fluid cytology in breast carcinoma.
  • BACKGROUND: Nipple aspirate fluid (NAF) cytology is a simple noninvasive method to study cells exfoliated into the ductal system of the breast.
  • In the current study, the significance of cytologic findings in NAF was determined by correlating them with histopathologic findings from corresponding breast tissue.
  • METHODS: Nipple aspirate fluid was collected by breast massaging and by using a breast aspiration device from 74 women with biopsy confirmed intraductal or invasive carcinoma with or without a history of preoperative neoadjuvant chemotherapy.
  • Cytologic findings were categorized as insufficient for diagnosis (less than 10 epithelial cells), benign, mild atypia, marked atypia or suspicious, and malignant.
  • Finally, they were correlated with tissue findings.
  • RESULTS: Nipple aspirate fluid was obtained from 74 women, including 24 who had received preoperative neoadjuvant chemotherapy.
  • Patients treated with chemotherapy had fewer epithelial cells in their NAF compared with patients who were not treated with chemotherapy.
  • Thirty specimens (41%) were inadequate for diagnosis, 34 were (46%) benign, 5 (7%) were mildly atypical, 1 (1%) was markedly atypical, and 4 (5%) were malignant.
  • Of the five cases with mildly atypical cytology, three were intraductal papilloma, one was low-grade papillary intraductal carcinoma, and one was low-grade intracystic papillary carcinoma with invasion in the corresponding tissue specimen.
  • The single case with markedly atypical NAF cytology had extensive ductal carcinoma in situ (DCIS).
  • Of the four cases with malignant NAF cytology, two were extensive DCIS and two had invasive carcinoma with extensive DCIS in the breast specimen.
  • Nipple aspirate fluid is not a sensitive test for detecting invasive carcinoma of the breast.
  • Atypical cytology in NAF is associated with papillary lesions in the underlying breast.
  • [MeSH-major] Breast / cytology. Breast / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Nipples

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12704689.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Maounis N, Chorti M, Legaki S, Ellina E, Emmanouilidou A, Demonakou M, Tsiafaki X: Metastasis to the breast from an adenocarcinoma of the lung with extensive micropapillary component: a case report and review of the literature. Diagn Pathol; 2010;5:82
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to the breast from an adenocarcinoma of the lung with extensive micropapillary component: a case report and review of the literature.
  • Breast metastasis from extra-mammary malignancy is rare.
  • The primary malignancies most commonly metastasizing to the breast are leukemia-lymphoma, and malignant melanoma.
  • We present a case of metastasis to the breast from a pulmonary adenocarcinoma, with extensive micropapillary component, diagnosed concomitantly with the primary tumor.
  • Additionally, on physical examination a poorly defined mass was noted in the upper outer quadrant of the left breast.
  • The patient underwent bronchoscopy, excisional breast biopsy and medical thoracoscopy.
  • By cytology, histology and immunohistochemistry primary lung adenocarcinoma with metastasis to the breast and parietal pleura was diagnosed.
  • The patient received chemotherapy but passed away within 7 months.
  • Accurate differentiation of metastatic from primary carcinoma is of crucial importance because the treatment and prognosis differ significantly.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Carcinoma, Papillary / secondary. Lung Neoplasms / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy. Bronchoscopy. Chemotherapy, Adjuvant. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Mammography. Predictive Value of Tests. Thoracoscopy. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Ultrasound Med. 2000 Apr;19(4):257-62 [10759349.001]
  • [Cites] J Surg Oncol. 2010 Feb 1;101(2):137-40 [20082359.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2259-66 [11745279.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Virchows Arch. 2002 Apr;440(4):353-61 [11956814.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1825-6 [12820464.001]
  • [Cites] Med Oncol. 2003;20(2):181-4 [12835522.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):137-41 [19875957.001]
  • [Cites] Mod Pathol. 2010 May;23(5):654-61 [20173733.001]
  • [Cites] Diagn Pathol. 2010;5:37 [20565809.001]
  • [Cites] Am Surg. 2004 Apr;70(4):287-90 [15098776.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):297-303 [15505530.001]
  • [Cites] Cancer. 1972 Jun;29(6):1691-6 [4337956.001]
  • [Cites] AJR Am J Roentgenol. 1977 Oct;129(4):673-6 [409241.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Jul;89(4):251-6 [7315321.001]
  • [Cites] Acta Oncol. 1992;31(4):479 [1632985.001]
  • [Cites] South Med J. 1997 Oct;90(10):1063-4 [9347825.001]
  • [Cites] Australas Radiol. 1998 Feb;42(1):16-9 [9509597.001]
  • [Cites] Acta Chir Belg. 2005 Feb;105(1):59-61 [15790204.001]
  • [Cites] APMIS. 2006 May;114(5):381-5 [16725015.001]
  • [Cites] Breast J. 2006 Jul-Aug;12(4):366-7 [16848849.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):103-13 [17145637.001]
  • [Cites] Australas Radiol. 2007 Apr;51(2):133-8 [17419856.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):731-7 [17582626.001]
  • [Cites] South Med J. 2007 Aug;100(8):850-1 [17715476.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1333-41 [18042689.001]
  • [Cites] Arch Pathol Lab Med. 2008 Feb;132(2):239-43 [18251583.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):426-32 [18300807.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):682-7 [18048381.001]
  • [Cites] Pathology. 2008 Jun;40(4):345-51 [18446623.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1299-301 [18505069.001]
  • [Cites] APMIS. 2009 Oct;117(10):762-7 [19775345.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2009 Oct;57(10):534-9 [19830516.001]
  • [Cites] Eur Radiol. 2001;11(9):1659-65 [11511887.001]
  • (PMID = 21167048.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] Adenocarcinoma of lung
  • [Other-IDs] NLM/ PMC3018363
  •  go-up   go-down


Advertisement
4. Bugat R, Bataillard A, Lesimple T, Voigt JJ, Culine S, Lortholary A, Merrouche Y, Ganem G, Kaminsky MC, Negrier S, Perol M, Laforêt C, Bedossa P, Bertrand G, Coindre JM, Fizazi K, FNCLCC, CRLCC: [Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site]. Bull Cancer; 2002 Oct;89(10):869-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site].
  • [Transliterated title] Standards, Options et Recommandations 2002 pur la prise en charge des patients atteints de carcinomes de site primitif inconnu (rapport abrégé).
  • OBJECTIVES: To develop clinical practice guidelines for carcinoma of unknown primary site (CUPS) patients according to the definitions of the Standards, Options and Recommendations project.
  • 1) An adapted immunochemistry test using a specific antibody battery should be performed for the anatomopathologic diagnosis.
  • 2) The aim of the diagnosis is to identify specific anatomoclinical forms that can be treated by a specific treatment (standard, level of evidence B2).
  • Except these forms, searching for the primary tumor site have no prognosis or therapeutic interest that can justify a systematic diagnosis assessment (standard, level of evidence B2).
  • 3) The management of poorly differentiated neuroendocrine carcinoma consists of platin/etoposide based chemotherapy.
  • There is no standard treatment for the differentiated forms.
  • 4) Surgical node excision and adjuvant radiotherapy should be performed in case of epidermoid carcinoma with cervical node metastases.
  • 5) The management of axillary node metastases in women with adenocarcinoma should be the same as the management of patients with lymph node metastases in breast cancer.
  • If mammary MRI is negative, surgical treatment and mammary irradiation are not recommended and an axillary node excision should be performed.
  • 6) The standard treatment for women with primary papillary serous carcinoma of the peritoneum is a surgical resection followed by chemotherapy, as recommended for ovarian cancer.
  • 7) CUPS not belonging to any specific anatomoclinical forms can be treated by chemotherapy, symptomatic treatment alone or treatment based on biphosphonates in presence bone metastases.
  • [MeSH-major] Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / therapy
  • [MeSH-minor] Axilla. Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Humans. Lymph Node Excision. Lymphatic Metastasis. Prognosis. Radiotherapy, Adjuvant. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12441278.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Guideline; Journal Article; Practice Guideline
  • [Publication-country] France
  •  go-up   go-down


5. Nakamura S, Kenjo H, Nishio T, Kazama T, Doi O, Suzuki K: Efficacy of 3D-MR mammography for breast conserving surgery after neoadjuvant chemotherapy. Breast Cancer; 2002;9(1):15-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of 3D-MR mammography for breast conserving surgery after neoadjuvant chemotherapy.
  • BACKGROUND: One of the main roles of neoadjuvant chemotherapy for breast cancer is to shrink large tumors to increase patient eligibility for breast conserving surgery.
  • METHODS: A total of 27 breast cancer cases were examined by 3D-MRM before and after neoadjuvant chemotherapy.
  • The volume reduction and shrinkage patterns were assessed and compared with the pathological diagnosis.
  • Twelve of 25 evaluable breast cancers (48%) showed a concentric shrinkage pattern while 13 cases (52%) showed a dendritic shrinkage pattern.
  • The cases with concentric shrinkage were good candidates for breast conserving surgery, But tumors showing dendritic shrinkage often had positive margins necessitating mastectomy.
  • Pathologically, tumors with a papillotubular pattern, Estrogen receptor (ER) positivity, low nuclear grade and c-erbB 2 negativity tended to show dendritic shrinkage.
  • CONCLUSIONS: 3D-MRM is a useful modality for evaluating whether breast conserving surgery can be safely done in the neoadjuvant setting.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Carcinoma, Papillary / pathology. Magnetic Resonance Imaging / standards. Mammography / standards
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans. Imaging, Three-Dimensional. Mastectomy, Segmental. Neoadjuvant Therapy. Neoplasm Staging / methods. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12196716.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


6. Fayanju OM, Ritter J, Gillanders WE, Eberlein TJ, Dietz JR, Aft R, Margenthaler JA: Therapeutic management of intracystic papillary carcinoma of the breast: the roles of radiation and endocrine therapy. Am J Surg; 2007 Oct;194(4):497-500
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic management of intracystic papillary carcinoma of the breast: the roles of radiation and endocrine therapy.
  • BACKGROUND: The role of radiation and endocrine therapy in the treatment of intracystic papillary carcinoma (IPC) remains unclear.
  • The aim of the current study was to review the management of IPC in order to determine factors associated with use of adjuvant therapies.
  • These patients were further divided into those with pure IPC (n = 21), IPC with associated ductal carcinoma in situ (DCIS) (n = 18), and IPC with associated microinvasion with or without DCIS (n = 6).
  • RESULTS: Patients with IPC and microinvasion were more likely to undergo an axillary staging procedure (6/6, 100%) compared to patients with pure IPC (6/21, 29%) or IPC with DCIS (5/18, 28%) (P < .001).
  • Patients with pure IPC were less likely to have radiation therapy than patients with IPC and DCIS or microinvasion (P < .001).
  • However, within the subset of patients with pure IPC, women less than 50 years of age were more likely to have radiation therapy than those older than 50 years (P < .001).
  • Patients with IPC and DCIS or microinvasion had significantly increased use of endocrine therapy versus patients with pure IPC (P < .01).
  • CONCLUSIONS: In our patient population, those patients with IPC and associated DCIS or microinvasion are treated with adjuvant radiation and endocrine therapy on the basis of this associated pathology.
  • The use of adjuvant radiation and/or endocrine therapy should be considered in patients with pure IPC who are of young age (<50 years).
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826064.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


7. Ng JS, Han AC, Edelson MI, Rosenblum NG: Uterine papillary serous carcinoma presenting as distant lymph node metastasis. Gynecol Oncol; 2001 Mar;80(3):417-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine papillary serous carcinoma presenting as distant lymph node metastasis.
  • BACKGROUND: Uterine papillary serous carcinomas are highly aggressive malignancies that often present with high-stage disease.
  • One case was found incidentally at the time of axillary dissection for breast cancer and the second case in the workup of a neck mass.
  • Both cases showed high-grade papillary carcinomas with psammoma bodies metastatic to lymph nodes in the axilla or neck.
  • Sampling of the endometrium in these patients confirmed primary uterine papillary serous carcinoma.
  • Patients were treated with adjuvant chemotherapy.
  • CONCLUSIONS: Metastatic uterine papillary serous carcinoma presenting initially in distant sites is an unusual manisfestation of this highly aggressive tumor.
  • This tumor should be considered in the differential diagnosis when patients present with metastatic high-grade papillary serous carcinomas and the primary site is unknown.
  • [MeSH-major] Cystadenocarcinoma, Papillary / pathology. Lymph Nodes / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Axilla. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neck

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11263944.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK: Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomarkers Prev; 2007 Jul;16(7):1400-7
MedlinePlus Health Information. consumer health - Female Infertility.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study.
  • BACKGROUND: Few epidemiologic studies have examined the association between fertility drugs and breast cancer risk, and results have been contradicting.
  • Using data from the largest cohort of infertile women to date, the aim of this study was to examine the effects of fertility drugs on breast cancer risk overall and according to histologic subtypes.
  • A detailed data collection, including information of type and amount of treatment, was conducted.
  • We used case-cohort techniques to calculate rate ratios (RR) of breast cancer associated with use of five groups of fertility drugs, after adjustment for parity status.
  • RESULTS: Three hundred thirty-one invasive breast cancers were identified in the cohort during follow-up through 1998.
  • Analyses within cohort showed no overall increased breast cancer risk after use of gonadotrophins, clomiphene, human chorionic gonadotrophin, or gonadotrophin-releasing hormone, whereas use of progesterone increased breast cancer risk (RR, 3.36; 95% confidence interval, 1.3-8.6).
  • For all groups of fertility drugs, no relationships with number of cycles of use or years since first use of fertility drug were found.
  • However, gonadotrophins may have a stronger effect on breast cancer risk among nulliparous women (RR, 1.69; 95% confidence interval, 1.03-2.77).
  • CONCLUSION: The results showed no strong association between breast cancer risk and use of fertility drugs.
  • Follow-up is, however, needed to assess long-term breast cancer risk after use of progesterone and among nulliparous women exposed to gonadotrophins.
  • [MeSH-major] Breast Neoplasms / epidemiology. Fertility Agents, Female / administration & dosage. Infertility, Female / drug therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adolescent. Adult. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / epidemiology. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / epidemiology. Case-Control Studies. Cohort Studies. Denmark / epidemiology. Female. Humans. Incidence. Middle Aged. Population Surveillance. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585058.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fertility Agents, Female
  •  go-up   go-down


9. Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, Lu KH: Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol; 2003 Dec;91(3):463-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.
  • OBJECTIVE: The aim of this study was to identify clinical and pathologic characteristics of patients with uterine papillary serous carcinoma (UPSC) who were all surgically managed at a single institution.
  • The median age at the time of diagnosis was 68 years (range, 44-93 years).
  • A personal history of breast cancer was reported by 12.4% of the patients, and a family history of breast cancer was reported by 16%.
  • Among stage III patients, those who received chemotherapy had a longer OS than those who did not receive chemotherapy (P = 0.03).
  • CONCLUSION: In this population of nonselected patients with UPSC, approximately 20% had a personal or family history of breast cancer.
  • [MeSH-major] Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / surgery. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2003 Dec;91(3):461-2 [14675662.001]
  • (PMID = 14675663.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


10. Chen L, Fan Y, Lang RG, Guo XJ, Sun YL, Fu L: [Diagnosis and prognosis study of breast carcinoma with micropapillary component]. Zhonghua Bing Li Xue Za Zhi; 2007 Apr;36(4):228-32
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and prognosis study of breast carcinoma with micropapillary component].
  • OBJECTIVE: To study the diagnostic criteria, clinicopathologic characteristics and prognosis of invasive micropapillary carcinoma (IMPC) of breast.
  • METHODS: All cases of breast carcinoma diagnosed during the period from 1989 to 2001 were retrospectively reviewed.
  • One hundred examples with IMPC component, according to the 2003 World Health Organization classification of breast tumors, were identified.
  • Univariate and multivariate analysis showed that the prognosis of patients was adversely affected by the presence of lymphovascular invasion and family history of breast cancer.
  • On the other hand, tamoxifen therapy and adjuvant chemotherapy improved survival.
  • CONCLUSIONS: Breast carcinoma with IMPC component is associated with poor prognosis, despites the relative proportion of this architectural pattern.
  • The overall prognosis is related to the presence of lymphovascular invasion and family history of breast cancer.
  • Hormonal therapy and individualized chemotherapy can improve the survival rate.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Papillary / diagnosis. Mastectomy / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Genetic Predisposition to Disease. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Methotrexate / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Tamoxifen / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706112.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen
  •  go-up   go-down


11. Ozsaran AA, Dikmen Y, Terek MC, Ulukus M, Ozdemir N, Orgüc S, Erhan Y: Bilateral metastatic carcinoma of the breast from primary ovarian cancer. Arch Gynecol Obstet; 2000 Nov;264(3):166-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral metastatic carcinoma of the breast from primary ovarian cancer.
  • During the courses of chemotherapy; bilateral breast nodules, and bilateral axillary lymphadenopathies and a nodule in the vaginal cuff were identified.
  • The biopsy of both breasts, axillary lymph nodes and the nodule in the vaginal cuff revealed papillary serous cystadenocarcinoma.
  • Immunohistochemical staining of breast specimens were positive for ovarian tumor marker CA-125.
  • [MeSH-major] Breast Neoplasms / secondary. Cystadenocarcinoma / secondary. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Axilla. CA-125 Antigen / metabolism. Female. Humans. Lymphatic Metastasis. Pleural Effusion, Malignant. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / metabolism. Vaginal Neoplasms / secondary


12. Ramalingam P, Middleton LP, Tamboli P, Troncoso P, Silva EG, Ayala AG: Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features. Ann Diagn Pathol; 2003 Apr;7(2):112-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features.
  • Carcinomas with micropapillary features have been described in the breast, urinary bladder, lung, and ovary.
  • The metastatic carcinoma can consist exclusively of the micropapillary component, which may elicit an erroneous diagnosis if located in the bladder or lung, as in the patient presented herein.
  • We present a case of a 59-year-old woman with a history of bilateral breast carcinoma status post-bilateral mastectomy, chemotherapy, and tamoxifen therapy.
  • A biopsy of the endometrium revealed a poorly differentiated carcinoma.
  • Urinary bladder biopsies showed a carcinoma with micropapillary features diagnosed as micropapillary transitional cell carcinoma.
  • Anderson Cancer Center (Houston, TX) for further treatment recommendations.
  • The mastectomy specimen showed an invasive ductal carcinoma with a significant micropapillary component.
  • The tumor cells from the breast, endometrium, and urinary bladder were positive for cytokeratin (CK) 7 and estrogen receptor and negative for CK20.
  • In view of the morphologic and immunohistochemical profile, the carcinoma in the endometrium and urinary bladder were interpreted as metastatic lesions from the breast primary.
  • Carcinomas with a micropapillary component are morphologically identical in the breast, urinary bladder, and lung.
  • However, micropapillary serous carcinoma has a different appearance more akin to borderline tumors of the ovary.
  • Immunohistochemical stains are useful in distinguishing these lesions in that thyroid transcription factor-1 positivity suggests a lung primary, CK7 and estrogen receptor suggest a breast primary, and both CK7 and CK20 positivity suggest a urinary bladder primary.
  • It is important to exclude metastatic carcinomas with micropapillary features before making a definite diagnosis of a primary tumor.
  • This article discusses the differential diagnosis of carcinomas with micropapillary features in different organs.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma, Papillary / secondary. Endometrial Neoplasms / secondary. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Keratins / metabolism. Lung Neoplasms / metabolism. Middle Aged. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12715337.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Receptors, Estrogen; 68238-35-7 / Keratins
  •  go-up   go-down


13. Niu Y, Fu XL, Yu Y, Wang PP, Cao XC: Intra-operative frozen section diagnosis of breast lesions: a retrospective analysis of 13,243 Chinese patients. Chin Med J (Engl); 2007 Apr 20;120(8):630-5
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-operative frozen section diagnosis of breast lesions: a retrospective analysis of 13,243 Chinese patients.
  • BACKGROUND: Although cytological methods for breast oncology have been used in recent decades, intra-operative frozen section has been playing a vital role in making therapeutic decisions.
  • We analyzed a large series of frozen section diagnoses for Chinese cases of breast lesion within the last 15 years.
  • The experience was expected to increase the diagnostic accuracy of cases with breast lesions.
  • METHODS: The data from consecutive 13243 cases of breast lesions diagnosed with intra-operative frozen sections between 1988 to 2002 were compared with paraffin sections in a case by case manner.
  • The diagnosis of 47 cases (0.4%) was delayed.
  • Six types (false invasion, peri-papilloma, adenoma of nipple duct, florid adenosis, sclerosing adenosis, and granulose cell tumor) of lesions may lead to false positive, and four types (morphological changes responding chemotherapy, well differentiated papillary carcinoma, invasive lobular carcinoma, and tubular carcinoma) to a false negative.
  • Gross and microscopic findings may be inconsistent in two types of lesions (radial scar and florid adenosis) microscopic and clinical findings in three types (ganulomatous mastitis mammary, duct ectasia, and fat necrosis), and three types (abundant fat or sclerous tissues; borderline lesions and changes of post-chemotherapy) were likely wrongly classified.
  • CONCLUSIONS: Intra-operative frozen section can accurately identify breast lesions in many instances, leading to fewer errors on account of more diagnostic experience and understanding of diagnostic limitations.
  • [MeSH-major] Breast Diseases / diagnosis. Breast Neoplasms / diagnosis. Frozen Sections / methods
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Biopsy / methods. Breast / pathology. Child. China. Female. Humans. Intraoperative Care / methods. Male. Middle Aged. Paraffin Embedding / methods. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17517175.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Hill KA, Rosen B, Shaw P, Causer PA, Warner E: Incidental MRI detection of BRCA1-related solitary peritoneal carcinoma during breast screening--A case report. Gynecol Oncol; 2007 Oct;107(1):136-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental MRI detection of BRCA1-related solitary peritoneal carcinoma during breast screening--A case report.
  • BACKGROUND: The reported cumulative risk of developing primary peritoneal carcinoma (PPC) one to 20 years after prophylactic bilateral oophorectomy is 3.5% to 4.3%.
  • After four cycles of chemotherapy a localized, grade 3 serous papillary adenocarcinoma was resected followed by further chemotherapy and radiation.
  • She remains disease-free 3 years post-treatment.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Genes, BRCA1. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Breast Neoplasms / genetics. Fallopian Tubes / surgery. Female. Genetic Predisposition to Disease. Germ-Line Mutation. Humans. Incidental Findings. Magnetic Resonance Imaging. Middle Aged. Ovariectomy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629551.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Kitajima A, Amano S, Sakurai K, Enomoto K, Matsuo S, Negishi N, Oinuma T, Nemoto N: [A case of breast cancer detected by MRI mammography after Hollywood syndrome]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1786-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of breast cancer detected by MRI mammography after Hollywood syndrome].
  • A-64-year-old woman, who had been treated with augmentation mammaplasty 40 years ago, came to our hospital complaining of left breast pain.
  • The mass was ill-defined, located in the upper outer quadrant area of her breast, and was 2 cm in diameter.
  • The diagnosis was Class IV by the fine needle aspiration biopsy cytology.
  • We diagnosed the left breast cancer being in T2N0M0, Stage IIA, then we carried out Bt (Auchincloss method) and Sentinel lymph node biopsy (SLNB).
  • The histological diagnosis was papillotubular carcinoma, f+, n+ (8/11).
  • We dosed 6 cycles of FEC chemotherapy (CPA 800 mg, EPI 80 mg, 5-FU 750 mg/body x 1 cycle).
  • We recognized no side effects of the chemotherapy for the patient.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Implants. Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Epirubicin. Female. Fluorouracil. Humans. Middle Aged. Sentinel Lymph Node Biopsy


16. Xue Y, Guo XT, Liu WC: [Clinical research advancement on male breast cancer]. Ai Zheng; 2007 Oct;26(10):1148-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical research advancement on male breast cancer].
  • Male breast cancer is a rare disease and the incidence has increased over the past 25 years.
  • Current knowledge regarding its biology, natural history, and treatment strategies is mainly based on the research findings on female breast cancer.
  • Hormonal imbalances, such as gonadal dysfunction, obesity, and radiation exposure also contribute to the occurrence of male breast cancer.
  • Most cases are ductal tumors and 10% of the cases are ductal carcinoma in situ.
  • Indications for radiotherapy, as well as the steps and methods, are similar to that for female breast cancer.
  • Because 90% of the patients are estrogen receptor-positive, tamoxifen is a standard adjuvant therapy, but some individuals could also benefit from chemotherapy.
  • In this article, the latest information on the epidemiology, biology, and treatment of male breast cancer is reviewed.
  • [MeSH-major] Breast Neoplasms, Male / therapy. Carcinoma, Ductal, Breast / therapy. Mastectomy / methods. Tamoxifen / therapeutic use
  • [MeSH-minor] Animals. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis Regulatory Proteins. BRCA2 Protein / genetics. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Fluorouracil / therapeutic use. Humans. Male. Methotrexate / therapeutic use. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927890.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human; 094ZI81Y45 / Tamoxifen; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF protocol
  • [Number-of-references] 47
  •  go-up   go-down


17. Varras M, Akrivis Ch, Bellou A, Malamou-Mitsi VD, Antoniou N, Tolis C, Salamalekis E: Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up. Eur J Gynaecol Oncol; 2004;25(5):640-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up.
  • Preoperative diagnosis of fallopian tube carcinoma is difficult due to the rarity and silent course of this neoplasm.
  • We present herein the case of a 58-year-old woman with primary fallopian tube carcinoma that was diagnosed preoperatively on the basis of a positive for adenocarcinoma Papanicolaou vaginal smear, repeated episodes of vaginal bleeding, negative endocervical and endometrial curettage, characteristic features on ultrasonography and elevated CA-125 levels.
  • Pathologic confirmation of primary serous papillary adenocarcinoma of the left fallopian tube was made.
  • FIGO stage was considered as IIIb and the patient received six courses of combined carboplatin-taxol chemotherapy.
  • At two years from onset of therapy the patient underwent a modified radical mastectomy and lymphadenectomy because of primary carcinoma of the right breast.
  • The patient was started on tamoxifen therapy, which she is still taking.
  • In conclusion, our study suggests an association between fallopian tube carcinoma and breast cancer and a good response of the patient to platinum-based chemotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Cystadenocarcinoma, Papillary / diagnosis. Fallopian Tube Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Estrogen Antagonists / therapeutic use. Female. Humans. Mastectomy. Middle Aged. Neoplasm Staging. Postoperative Period. Preoperative Care. Tamoxifen / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493187.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


18. Kayikçioğlu F, Boran N, Ayhan A, Güler N: Inflammatory breast metastases of ovarian cancer: a case report. Gynecol Oncol; 2001 Dec;83(3):613-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory breast metastases of ovarian cancer: a case report.
  • BACKGROUND: Metastasis to the breast from extramammary malignancies is rare.
  • CASE: A 35-year-old woman presented with bilaterally inflammatory breast involvement, 2 years after the diagnosis of stage IIIC epithelial ovarian cancer.
  • Neoplastic tissue was immunohistochemically positive using antibodies against OC125 and negative for gross cystic disease fluid protein-15 (BRST-2) and estrogen receptor in biopsy material in the breast.
  • Combination chemotherapy consisting of paclitaxel, cisplatin, and anthracycline was started.
  • She died 18 months after the breast metastasis.
  • CONCLUSION: Ovarian carcinoma usually presents with signs and symptoms related to the tumor burden within the abdominal cavity.
  • The finding of isolated, distant metastases such as breast involvement without intraabdominal disease is extremely rare.
  • Determining the origin of the primary tumor is important in directing the actual therapy.
  • [MeSH-major] Breast Neoplasms / secondary. Cystadenocarcinoma, Papillary / secondary. Ovarian Neoplasms / pathology


19. Kilic-Okman T, Yardim T, Gücer F, Altaner S, Yuce MA: Breast cancer, ovarian gonadoblastoma and cervical cancer in a patient with Peutz-Jeghers Syndrome. Arch Gynecol Obstet; 2008 Jul;278(1):75-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer, ovarian gonadoblastoma and cervical cancer in a patient with Peutz-Jeghers Syndrome.
  • Patients with PJS have increased risk for gastrointestinal, breast, and female genital tract cancers.
  • In 2003, concomitant to cervical carcinoma, breast cancer was diagnosed.
  • Patient underwent left modified radical mastectomy due to the invasive papillary carcinoma.
  • The patient received six cycles combination chemotherapy and radiation therapy because of stage IIIB cervical cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Gonadoblastoma / diagnosis. Ovarian Neoplasms / diagnosis. Peutz-Jeghers Syndrome / complications. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Biomarkers, Tumor / blood. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / surgery. Fatal Outcome. Female. Humans. Mastectomy. Neoplasms, Multiple Primary


20. Leboeuf R, Bénard F, Langlois MF: Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid. Clin Nucl Med; 2006 Jul;31(7):382-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid.
  • Furthermore, a relationship between breast and thyroid carcinoma has been previously proposed.
  • CASE DESCRIPTION: We describe the case of a 59-year-old woman who presented with simultaneous papillary and breast carcinoma within the thyroid gland.
  • F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) done for the evaluation of her metastatic breast cancer revealed a thyroid incidentaloma with a high metabolic rate (standardized uptake value [SUV] of 13).
  • She underwent thyroidectomy and the pathology revealed papillary thyroid carcinoma corresponding to the lesion visualized on FDG PET.
  • However, small metastatic implants of breast carcinoma were seen within the opposite thyroid lobe.
  • CONCLUSION: This is a rare description of a concomitant papillary thyroid carcinoma presenting as an FDG PET incidentaloma alongside breast cancer metastases to the thyroid gland.
  • Thyroid and breast cancer sometimes occur in the same patient.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Papillary / radionuclide imaging. Estrogens. Incidental Findings. Neoplasms, Hormone-Dependent / radionuclide imaging. Neoplasms, Hormone-Dependent / secondary. Neoplasms, Second Primary / radionuclide imaging. Positron-Emission Tomography. Thyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / secondary
  • [MeSH-minor] Adrenal Gland Neoplasms / secondary. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Female. Fluorodeoxyglucose F18. Humans. Iodine Radioisotopes / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Mastectomy, Segmental. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / secondary. Middle Aged. Neoplasm Proteins / analysis. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / radiography. Neoplasms, Radiation-Induced / radionuclide imaging. Radiopharmaceuticals / therapeutic use. Radiotherapy, Adjuvant. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Tamoxifen / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785803.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 0 / Iodine Radioisotopes; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 094ZI81Y45 / Tamoxifen; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


21. André F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S: Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol; 2009 Apr;10(4):381-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.
  • BACKGROUND: Gene-expression arrays have generated molecular predictors of relapse and drug sensitivity in breast cancer.
  • We aimed to identify exons differently expressed in malignant and benign breast lesions and to generate a molecular classifier for breast-cancer diagnosis.
  • METHODS: 165 breast samples were obtained by fine-needle aspiration.
  • A nearest centroid prediction rule was developed to classify lesions as malignant or benign on a training set, and its performance was assessed on an independent validation set.
  • FINDINGS: 120 breast cancers and 45 benign lesions were included in the study.
  • A molecular classifier for breast-cancer diagnosis with 1228 probe sets was generated from the training set (n=94).
  • In the same population of 165 samples, 956 exon probe sets presented both higher intensity and higher splice index in breast cancer than in benign lesions, although located on unchanged genes.
  • INTERPRETATION: Many exons are differently expressed by breast cancer and benign lesions, and alternative transcripts contribute to the molecular characteristics of breast malignancy.
  • Development of molecular classifiers for breast-cancer diagnosis with fine-needle aspiration should be possible.
  • [MeSH-major] Breast Neoplasms / genetics. Exons / genetics. Gene Expression Profiling. Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Carcinoma, Lobular / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA Splicing / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Validation Studies as Topic. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Apr;10(4):314-5 [19341968.001]
  • (PMID = 19249242.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


22. Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S: Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. Am J Clin Pathol; 2008 Apr;129(4):563-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
  • We performed a technical and cost-effectiveness analysis of quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR) for the assessment of HER2 in breast cancer.
  • We evaluated 44 frozen and 55 formalin-fixed paraffin-embedded (FFPE) breast carcinoma specimens by Q-RT-PCR, immunohistochemical analysis, and fluorescent in situ hybridization (FISH).
  • Immunohistochemical and FISH analyses were performed on individual slides and on tissue microarray.
  • Cost analysis documented the advantage of Q-RT-PCR in all US Food and Drug Administration-approved assays.
  • Our data support the use of Q-RT-PCR for testing breast cancer specimens to select patients for HER2 inhibitory therapy.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Receptor, ErbB-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction / economics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apocrine Glands / metabolism. Apocrine Glands / pathology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Cost-Benefit Analysis. Female. Gene Expression. Humans. In Situ Hybridization, Fluorescence / economics. In Situ Hybridization, Fluorescence / methods. Middle Aged. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Sweat Gland Neoplasms / genetics. Sweat Gland Neoplasms / metabolism. Sweat Gland Neoplasms / pathology. Tissue Array Analysis / economics. Tissue Array Analysis / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343783.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


23. Kolwijck E, Boss EA, van Altena AM, Beex LV, Massuger LF: Stage IV epithelial ovarian carcinoma in an 18 year old patient presenting with a Sister Mary Joseph's nodule and metastasis in both breasts: a case report and review of the literature. Gynecol Oncol; 2007 Dec;107(3):583-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV epithelial ovarian carcinoma in an 18 year old patient presenting with a Sister Mary Joseph's nodule and metastasis in both breasts: a case report and review of the literature.
  • CASE: We describe an 18-year-old girl presenting with umbilical metastasis as a first sign of an extremely aggressive stage IV ovarian serous papillary adenocarcinoma without an objective response to chemotherapy and endocrine therapy.
  • She developed metastasis in both breasts and died 28 months after the initial diagnosis.
  • Furthermore, uncommon breast metastasis and a Sister Mary Joseph's nodule have never been described at such young age.
  • [MeSH-major] Breast Neoplasms / secondary. Ovarian Neoplasms / pathology. Umbilicus / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / secondary. Adolescent. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / secondary. Female. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17904207.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Penel N: [Prognosis and possibilities of treatment of inaugural metastases]. Presse Med; 2003 Jun 14;32(21):997-1004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis and possibilities of treatment of inaugural metastases].
  • [Transliterated title] Pronostic et possibilités thérapeutiques des métastases inaugurales.
  • Treatment of specific clinical forms Cervical node metastases revealing an unfound epidermoid carcinoma require surgical node excision and radiotherapy.
  • Axillary node metastases in woman require lymph node excision and systemic adjuvant therapy, similar to that used in breast cancer.
  • The management of peritoneal serous papillary carcinomatosis in women consists in chemotherapy as in ovarian cancer, combined with debulking surgery.
  • Median line syndrome requires radiotherapy or chemotherapy (with a cisplatin-etoposide combination or the regimen used for treatment of germ-cell tumours).
  • Other therapeutic possibilities Excluding these forms, no chemotherapy regimen is a gold standard.
  • There is little data on locoregional treatments.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Unknown Primary
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12876531.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 73
  •  go-up   go-down


25. Bland AE, Calingaert B, Secord AA, Lee PS, Valea FA, Berchuck A, Soper JT, Havrilesky L: Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol; 2009 Jan;112(1):150-4
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between tamoxifen use and high risk endometrial cancer histologic types.
  • OBJECTIVES: We wished to determine whether a pre-existing diagnosis of breast cancer or the use of tamoxifen among patients with pre-existing breast cancer influences the histologic type of subsequently diagnosed endometrial carcinoma, the interval between these diagnoses, or survival.
  • METHODS: A single institution retrospective review was performed of all patients who underwent primary surgery for endometrial carcinoma from 1995-2005.
  • We compared the histologic type of endometrial carcinoma among patients with a prior history of breast cancer to those without.
  • Patients with a previous diagnosis of breast cancer were further analyzed by comparing histologic type, progression-free and overall survival between tamoxifen users and non-users.
  • RESULTS: Among 732 women with endometrial carcinoma, 59 patients (8%) had a previous diagnosis of breast cancer, of whom 29 (49%) had used tamoxifen.
  • Women with a history of breast cancer were more likely to have a high risk uterine histologic type (grade 3 endometrioid, papillary serous, or clear cell) (18/59; 31%) than those without this prior malignancy (120/670, 18%; p=0.024).
  • Breast cancer survivors whose endometrial carcinoma was of a high risk histologic type had a longer median duration of prior tamoxifen use compared to those with lower risk histologic types (60 versus 46 months, p=0.034).
  • CONCLUSIONS: Among women with endometrial carcinoma, those with a history of breast cancer are more likely to harbor a high risk uterine histologic subtype.
  • This study adds to existing data suggesting a relationship between tamoxifen use and development of endometrial carcinoma of more aggressive histologic types.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Endometrial Neoplasms / pathology. Neoplasms, Second Primary / pathology. Selective Estrogen Receptor Modulators / administration & dosage. Tamoxifen / administration & dosage

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937966.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down






Advertisement